SAN RAFAEL, Calif.--(BUSINESS WIRE)--IMIDomics Inc., a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), today announced a strategic license and collaboration agreement with the University of Barcelona (UB). Under this agreement, IMIDomics has licensed cutting-edge technology and expertise from UB to advance research aimed at understanding and treating IMIDs..

加利福尼亚州圣拉斐尔-（商业线）-IMIDomics Inc.，一家专注于免疫介导的炎症性疾病（IMIDs）的以患者为中心的药物发现和开发公司，今天宣布与巴塞罗那大学签订战略许可和合作协议（UB）。根据该协议，IMIDomics已获得UB的尖端技术和专业知识，以推进旨在了解和治疗IMID的研究。。

Dr. H. Daniel Perez, Chief Development Officer at IMIDomics, expressed his enthusiasm for the partnership, stating, 'This collaboration marks a significant milestone for IMIDomics as we continue our relentless pursuit of novel therapies for IMIDs. We believe working closely with the University of Barcelona will help us accelerate our research and ultimately benefit patients suffering from IMIDs.'.

IMIDomics的首席开发官H.Daniel Perez博士对这种合作表示了他的热情，他说：“这项合作标志着IMIDomics的一个重要里程碑，因为我们继续不懈地追求IMIDs的新疗法。我们相信与巴塞罗那大学密切合作将有助于我们加速研究并最终使患有IMID的患者受益。

IMIDomics has established itself as a leader in IMID research, having identified crucial therapeutic targets using the company’s proprietary Clinical Discovery Engine™, a multidimensional, integrated, and data-driven platform for uncovering the underlying mechanisms of IMIDs. This license and collaboration with the University of Barcelona is a significant milestone and will further the company’s ongoing scientific discoveries and the development of IMIDomics’ drug targets IMB-1003 and IMB-1004 for the treatment of autoimmune diseases..

IMIDomics已经成为IMID研究的领导者，使用该公司专有的临床发现引擎确定了关键的治疗目标™, 一个多维，集成和数据驱动的平台，用于揭示IMID的潜在机制。这项许可证和与巴塞罗那大学的合作是一个重要的里程碑，将进一步推动该公司正在进行的科学发现以及用于治疗自身免疫性疾病的IMIDomics药物靶标IMB-1003和IMB-1004的开发。。

Under this agreement, IMIDomics will leverage UB’s innovative technology and its expertise in areas including biologics discovery as it advances IMB-1003 and IMB-1004 through two research projects aimed at developing new therapeutic approaches.

根据这项协议，IMIDomics将利用UB的创新技术及其在生物制剂发现等领域的专业知识，通过两个旨在开发新治疗方法的研究项目推进IMB-1003和IMB-1004。

'All of us at the University of Barcelona, including myself and Dr. Ana Angulo, are excited to collaborate with IMIDomics in advancing the frontiers of IMID research,” said Dr. Pablo Engel, Project Leader and Professor at the Faculty of Medicine and Health Sciences at the UB. “Through this partnership, we aim to uncover valuable insights and solutions that can make a meaningful difference in the lives of patients.'.

“巴塞罗那大学的我们所有人，包括我和Ana Angulo博士，都很高兴与IMIDomics合作推进IMID研究的前沿，”UB医学院项目负责人兼教授Pablo Engel博士说。和健康科学。“通过这种伙伴关系，我们的目标是发现有价值的见解和解决方案，可以在患者的生活中产生有意义的差异。”。

The licensing agreement encompasses all exclusive intellectual property, including patents and proprietary knowledge, related to specific technologies. While the financial specifics of the agreement are undisclosed, it encompasses initial payments, milestones, and royalties.

许可协议涵盖与特定技术相关的所有专有知识产权，包括专利和专有知识。虽然协议的财务细节未披露，但包括初始付款，里程碑和版税。

About IMIDomics

关于模仿

IMIDomics is a biotechnology company focused on patient-centric drug discovery for immune-mediated inflammatory diseases (IMIDs). Our goal is to discover new and impactful IMID drugs by focusing on carefully selected patients, and stratifying populations to identify those most likely to respond. IMIDomics is powered by a unique Clinical Discovery Engine™, which integrates and analyzes proprietary clinical, epidemiological and patient-derived biomolecular datasets, generated in partnership with the Vall d’Hebron Institute of Research, to establish a deeper understanding of IMID diseases.

IMIDomics是一家专注于以患者为中心的免疫介导炎症性疾病（IMIDs）药物发现的生物技术公司。我们的目标是通过专注于精心挑选的患者，发现新的和有影响力的IMID药物，并对人群进行分层以确定最有可能做出反应的人群。IMIDomics由独特的临床发现引擎提供动力™, 该公司整合并分析了与Vall d'Hebron研究所合作生成的专有临床，流行病学和患者衍生的生物分子数据集，以更深入地了解IMID疾病。

IMIDomics has identified previously unrecognized targets, six of which have been selected for development within IMIDomics’ active drug pipeline. By relying on access to well-defined patients and their clinically relevant samples, IMIDomics enhances the probability of successful IMID drug discovery and development for those in need..

IMIDomics已经确定了以前未被认识到的目标，其中六个已被选中在IMIDomics的活性药物管道中进行开发。通过获得明确定义的患者及其临床相关样本，IMIDomics提高了有需要者成功发现和开发IMID药物的可能性。。

To learn more about IMIDomics, please visit www.imidomics.com.

要了解有关IMIDomics的更多信息，请访问www.IMIDomics.com。

About the University of Barcelona (UB)

关于巴塞罗那大学（UB）

The University of Barcelona is a renowned institution committed to excellence in education and research across various fields. UB is an entity whose purpose is to execute a high level of research to contribute in the furtherance of knowledge, to improve the quality of life, to promote peace, the disappearance of the social and economic inequalities between people, to increase innovation and business competitiveness and, in general, the progress of science and artistic creation by means of the creation, transmission and dissemination to the society of the scientific, technical and professional knowledge that generates..

巴塞罗那大学是一所知名机构，致力于各个领域的教育和研究卓越。UB是一个实体，其目的是执行高水平的研究，为促进知识发展，改善生活质量，促进和平，消除人与人之间的社会和经济不平等，提高创新和商业竞争力，以及一般来说，通过创造来创造科学和艺术的进步，向社会传播和传播产生的科学，技术和专业知识。。

About Fundació Bosch i Gimpera (FBG): FBG is the Centre for the Transfer of Knowledge, Technology and Innovation of UB that protects, manages and negotiates the transfer of the intellectual property rights of UB.

关于FundacióboschiGimpera（FBG）：FBG是UB知识，技术和创新转移中心，保护，管理和谈判UB的知识产权转让。